Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Faron Pharmaceuticals Oy

Healthcare GB FARN

47.4GBX
1.40(3.04%)

Last update at 2026-06-04T15:36:00Z

Day Range

44.5047.40
LowHigh

52 Week Range

41.00270.00
LowHigh

Fundamentals

  • Previous Close 46.00
  • Market Cap61.69M
  • Volume48139
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.04800M
  • Revenue TTM1.31M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 1.31M
  • Diluted EPS TTM-0.19

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -27.24617M -0.02592M -30.94400M -28.73000M -21.17800M
Minority interest - - - - -
Net income -27.24817M -0.02592M -30.94400M -30.03400M -21.19400M
Selling general administrative 2.83M 6.68M 8.71M 7.50M 9.88M
Selling and marketing expenses - 0.25M 0.35M - -
Gross profit -0.32589M - - - -
Reconciled depreciation 0.33M 0.32M 0.35M 0.30M 0.31M
Ebit -20.26043M -0.01867M -28.56800M -27.42600M -21.10800M
Ebitda -19.93454M -0.01847M -28.37100M -27.03000M -20.63600M
Depreciation and amortization 0.33M 0.00020M 0.20M 0.40M 0.47M
Non operating income net other - - - - -
Operating income -20.26044M -0.01867M -28.56800M -27.42600M -21.10800M
Other operating expenses 20.26M 0.02M 28.57M 27.43M 21.11M
Interest expense 9.69M 0.00385M 2.17M 1.40M 0.23M
Tax provision 0.00200M 0.00500M 0.00000M 0.00000M 0.02M
Interest income 0.06M 0.09M 0.23M 0.01M 0.00200M
Net interest income -5.80400M -4.36600M -2.38300M -1.34900M -0.24500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00200M 0.00001M - 1.30M 0.02M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 19.93M 0.02M 28.57M 27.43M 21.11M
Cost of revenue 0.33M - - - -
Total other income expense net -6.98574M -0.00724M -2.37600M -1.30400M -0.07000M
Discontinued operations - - - - -
Net income from continuing ops -27.25700M -25.92000M -30.94400M -28.73000M -21.19400M
Net income applicable to common shares - - - -28.73000M -21.19400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 17.17M 12.52M 10.22M 11.27M 13.18M
Intangible assets 1.12M 1.11M 1.09M 1.15M 0.90M
Earning assets - - - - -
Other current assets 2.99M 1.36M 1.99M -0.00100M 5.17M
Total liab 35.67M 22.28M 25.38M 22.75M 10.26M
Total stockholder equity -18.50100M -9.76200M -15.16100M -11.47600M 2.92M
Deferred long term liab - - - - -
Other current liab 8.47M 1.46M 2.40M 2.45M 1.48M
Common stock 2.69M 2.69M 2.69M 2.69M 2.69M
Capital stock 2.69M 2.69M 2.69M 2.69M 2.69M
Retained earnings -222.78382M -197.42100M -172.20800M -143.71300M -116.26500M
Other liab - - - 1.01M 0.15M
Good will - - - - -
Other assets - - - 0.06M 0.05M
Cash 12.31M 9.50M 6.88M 6.99M 6.85M
Cash and equivalents - - - - -
Total current liabilities 18.87M 10.17M 15.01M 10.47M 7.18M
Current deferred revenue - - - - 2.86M
Net debt 12.36M 2.61M 6.24M 6.28M -3.30600M
Short term debt 10.40M 3.84M 3.64M 2.00M 0.61M
Short long term debt 10.27M 3.72M 3.48M 1.85M 0.43M
Short long term debt total 24.67M 12.11M 13.11M 13.27M 3.55M
Other stockholder equity - 184.97M 154.20M 129.55M 116.49M
Property plant equipment - - - 0.33M 0.21M
Total current assets 15.82M 11.06M 8.87M 9.73M 12.02M
Long term investments - - - - -
Net tangible assets - - - -12.63000M 2.02M
Short term investments - - - - -
Net receivables 0.51M 0.20M - 0.91M 1.42M
Long term debt 14.20M 8.09M 9.42M 11.10M 2.92M
Inventory - -0.20100M - - -
Accounts payable 5.54M 4.88M 8.97M 6.01M 2.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 201.59M 184.97M 0.15M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.04M 0.06M 0.06M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 1.35M 1.46M 1.35M 1.54M 1.16M
Capital lease obligations 0.21M 0.30M 0.21M 0.32M 0.20M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.22600M -0.12300M -0.38500M -0.47300M
Change to liabilities - - - 0.72M 0.72M
Total cashflows from investing activities -0.22193M -0.22600M -0.12300M -0.38500M -0.47300M
Net borrowings 16.11M -0.17100M -0.79700M 10.17M 0.35M
Total cash from financing activities 27.27M 25.82M 23.98M 23.48M 25.59M
Change to operating activities - - - 4.05M -2.48400M
Net income -27.24817M -25.92000M -30.94400M -28.73000M -21.19400M
Change in cash 3.30M 2.63M -0.11400M 0.14M 2.75M
Begin period cash flow 9.02M 6.88M 6.99M 6.85M 4.11M
End period cash flow 12.31M 9.50M 6.88M 6.99M 6.85M
Total cash from operating activities -24.34111M -22.97100M -23.80600M -22.99300M -22.21800M
Issuance of capital stock 12.12M 31.85M 26.03M 13.45M 25.56M
Depreciation 0.33M 0.32M 0.35M 0.30M 0.31M
Other cashflows from investing activities - -0.22500M - - 0.00100M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -1.94037M - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.14095M -5.86300M -1.25100M 10.14M 0.15M
Change to netincome - - - 0.67M 0.43M
Capital expenditures 0.22M 0.23M 0.12M 0.39M 0.47M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.20M -4.59800M 3.24M 4.77M -1.76100M
Stock based compensation 1.82M 0.69M 2.45M 1.30M 1.49M
Other non cash items 2.38M 6.54M 1.10M -0.62600M -1.17100M
Free cash flow -24.34111M -23.19700M -23.92900M -23.37800M -22.69200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FARN
Faron Pharmaceuticals Oy		 1.40 3.04% 47.40 - - 47.16 165.73 2347.87 -3.5272
GNS
Genus PLC		 38.00 1.70% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 5.50 4.09% 140.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 28.00 4.90% 600.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 70.00 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy

Joukahaisenkatu 6 B, Turku, Finland, 20520

Key Executives

Name Title Year Born
Dr. Juho Markku Jalkanen M.D., MSc, Ph.D. Chief Operating Officer 1978
Dr. Markku Tapani Jalkanen Ph.D. Founder, CEO & Exec. Director 1954
Mr. Toni Hänninen Chief Financial Officer NA
Dr. Maija Hollmen Ph.D. Chief Scientific Officer NA
Eric Van Zanten Head of Communications NA
Dr. Juhana Heinonen Chief Commercial Officer NA
Dr. Marie-Louise Fjallskog M.D., Ph.D. Chief Medical Officer 1964
Dr. Ilse Piippo Regulatory Consultant 1949
Dr. Juho Markku Jalkanen M.D., MSc, Ph.D. Founder, CEO & Director 1978
Mr. Jurriaan Dekkers Chief Financial Officer 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions